# Positron Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Positron Corp). ## Overview Positron Corp is a U.S.-based medical technology company focused on PET and PET-CT imaging systems for nuclear medicine. The company develops, manufactures, and sells imaging equipment and supports customers with maintenance services, clinical support, and related commercial arrangements from its headquarters in North Tonawanda, New York. ## Products & services • PET imaging systems • PET-CT imaging systems • Maintenance service contracts • Clinical and technical support • OEM supply and distribution arrangements - **PET and PET-CT imaging systems** (70%) — Capital equipment used for molecular imaging in cardiac, oncology, and neurology applications. - **Maintenance service contracts** (30%) — Recurring service agreements that provide ongoing support and system uptime for installed equipment. - PET imaging systems - PET-CT imaging systems - Maintenance service contracts - Clinical and technical support - OEM supply and distribution arrangements ## Customers Positron sells to healthcare providers that use molecular imaging for diagnosis and treatment planning, especially in nuclear cardiology. Its customer base includes hospitals, outpatient centers, and physician practices that need PET and PET-CT systems plus ongoing service support. The company also works through OEM and distribution arrangements that extend market access for its imaging platforms. - **Hospitals and health systems** (primary) — Buy PET and PET-CT systems for inpatient and outpatient diagnostic imaging and long-term service support. - **Outpatient imaging centers** (primary) — Purchase systems and maintenance contracts to offer molecular imaging without building in-house technology. - **Physician practices** (secondary) — Use Positron systems for specialized nuclear cardiology workflows and recurring service coverage. - **OEM and distribution partners** (secondary) — Support broader commercialization and market reach for PET and PET-CT products. - Hospitals buying PET-CT systems for cardiac and oncology imaging - Outpatient imaging centers seeking lower-cost molecular imaging equipment - Physician practices needing installed systems and service coverage - Nuclear cardiology users that value specialized PET workflow support - Customers purchasing maintenance contracts to keep systems operational - Distribution/OEM partners expanding access to the product line ## Geography Positron is headquartered in North Tonawanda, New York and is organized as a U.S. company. The reports emphasize North American commercialization, including an exclusive North American distribution right tied to its PET and PET-CT product line. Geography matters because the company’s market access, regulatory pathway, and installed-base service model are concentrated in the U.S. healthcare market. - Headquartered in North Tonawanda, New York - U.S. incorporation and primary operating base - North American market focus for PET and PET-CT commercialization - Distribution rights tied to the North American market - Healthcare demand is driven by U.S. nuclear medicine adoption ## Strategy Positron’s strategy centers on expanding its PET-CT offering, broadening use in nuclear cardiology, and supporting commercialization through manufacturing and distribution partnerships. The company also relies on external capital to fund operations while it builds revenue scale and expands clinical adoption of its imaging systems. - **Commercialize PET-CT systems in North America** (short-term) — Broader adoption is central to scaling the installed base and creating recurring service revenue. - **Expand clinical use cases beyond cardiac PET** (medium-term) — Oncology and neurology can enlarge the addressable market and reduce dependence on one specialty. - **Strengthen service and uptime support** (medium-term) — Maintenance contracts improve customer retention and support the value proposition of installed equipment. - Expand PET-CT adoption in nuclear cardiology - Use OEM and distribution cooperation to widen market access - Support installed systems with maintenance and technical services - Improve accessibility and affordability versus larger imaging platforms - Raise capital to fund operations and commercialization - Build clinical credibility in cardiac PET and adjacent indications ## Risks Positron faces execution risk in commercializing its imaging systems, including customer adoption, competitive pressure, and the need to secure financing to support operations. Because the business depends on equipment sales plus service contracts, delays in equipment acceptance or slower market uptake can affect revenue timing and cash generation. The company also depends on healthcare capital spending and regulatory/clinical acceptance in a specialized medical imaging market. - **Going-concern and financing risk** [critical] — The company states it may need additional capital to continue operations and fund growth. - **Customer adoption and market acceptance risk** [high] — PET and PET-CT systems require clinical acceptance and buyer confidence before scaling. - **Competitive risk** [medium] — The imaging market includes established competitors with broader product portfolios and sales reach. - **Revenue timing risk on equipment sales** [medium] — Revenue is recognized only when control transfers, so delayed delivery or acceptance postpones revenue. - Customer adoption risk for PET and PET-CT systems - Need for financing to fund operations and commercialization - Competitive pressure from larger imaging equipment vendors - Revenue timing risk when equipment transfer of control is delayed - Healthcare capital spending cycles can slow purchases - Specialized market concentration in nuclear cardiology ## Accounting Revenue recognition is a key accounting issue because maintenance contracts are recognized over time while equipment sales are recognized only when control transfers to the customer. Deferred revenue and customer deposits create contract liabilities that affect the timing of reported revenue and can make quarterly results uneven. The company also highlights judgment-heavy estimates and financial instrument accounting, which can materially affect reported liabilities and equity. - **Revenue recognition timing** — Reported revenue depends on service periods and equipment delivery/acceptance - **Deferred revenue and contract liabilities** — Affects balance sheet liabilities and future revenue visibility - **Financial instruments with liability/equity characteristics** — Can affect classification, dilution analysis, and equity balances - Maintenance revenue recognized ratably over the service term - Equipment revenue recognized at transfer of control and acceptance - Deferred revenue reflects advance billings and customer deposits - No equipment sale revenue recognized in the reported interim periods - Judgment in financial instruments with liability/equity features - Quarterly results can shift with contract timing and acceptance --- *Last updated: 2026-06-16T23:05:10.036155+00:00*